

**B7801001-
1002**

A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo -Controlled, First-in-human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06755347 After Single Ascending Intravenous and Subcutaneous Dosing in Healthy Adult Male Participants and Open-Label After Single Subcutaneous Dosing in Male and Female Participants with Persistent or Chronic Primary Immune Thrombocytopenia



EudraCT number:	2018-003315-21
Study medicine:	PF-06755347
Sponsor of the study:	Pfizer Inc.
Research organisation:	Pfizer Clinical Research Unit (PCRU), Route de Lennik 808, 1070 Brussels
Medical Ethics Committee:	Comité d’Ethique Hospitalo-Facultaire Erasme-ULB.
Principal Investigator:	Dr Isabelle Huyghe
Emergency contact:	0800 30 019/ +32(0) 2 556 70 03

I. Information vital to your decision to take part in the study

Introduction

You are being invited to take part in a clinical study to evaluate an investigational medicinal product. An investigational medicinal product is a medicinal product that is still being studied to evaluate its efficacy, safety, or mode of action.

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.

Before you agree to take part in this study, we invite you to take note of its implications in terms of organisation and possible risks, to allow you to take a decision with full awareness of the implications. This is called giving an “informed consent”.

Please read these few pages of information carefully and ask any questions you want to the investigator or his/her representative. There are 3 parts to this document:

- the information essential to your decision,
- your written informed consent and
- supplementary information (appendices) detailing certain aspects of the basic information.

If you take part in this clinical study, you should be aware that:

- This clinical study is being conducted after having been reviewed by one Ethics Committee.
- Your participation is voluntary and must remain free from any coercion. It requires the signature of a document expressing your consent. Even after having signed that document, you can stop participating in the study at any time, by informing the investigator of your decision.
- The data collected in the scope of the study are confidential and shall be processed in conformity with the General Data Protection Regulation and the Belgian law of 30 July 2018 relating to the protection of natural persons with regards to the processing of their personal data. Your anonymity is guaranteed during publication of the results.
- Insurance has been taken out in case you should suffer any damage in connection with your participation in this clinical study.
- You may contact the investigator or a member of his/her team at any time should you need any additional information.
- If you have expressed a specific consent for this, your general practitioner will be informed of your participation in this study. He/she will also be informed when the study is complete.

Further information about “Participant Rights” can be found in appendix (page 16).

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



Objectives and description of the study protocol

We are inviting you to take part in a clinical study involving PF-06755347 which will include around **75 participants**, including among these, up to 8 Japanese participants, in the Japanese cohort (Optional Cohort 12).

Maximum 12 patients are foreseen in this clinical study.

These 2 patient cohorts will be consented via a patient-specific consent form and are therefore out of scope of this document.

1. AIMS OF THE STUDY

The purpose of this research study is to learn about the impact of PF-06755347, the study medicine on your body, through single dose of PF-06755347 administered in **healthy participants** and in patients with persistent or chronic primary ITP.

The study will evaluate the safety, tolerability, and blood concentrations of PF-06755347 (= pharmacokinetics) when administered by intravenous infusion or by subcutaneous injection.

The pharmacodynamics of PF-06755347 will also be studied, which means that we will be evaluating changes in various biomarkers. A biomarker is a characteristic objectively measured and evaluated as an indicator of a disease or of the action of a drug. Thus, for example, glucose is a biomarker for diabetes and blood pressure is a biomarker for arterial hypertension.

Immunogenicity, i.e., the ability of PF-06755347 to induce an immune reaction by producing antibodies against PF-06755347 will also be evaluated.

2. LEGAL STATUS OF THE STUDY MEDICINES

PF-06755347 is a new investigational medicine. A new investigational medicine is one that is currently not approved for sale in this country.

PF-06755347 is a new drug that is currently being developed by Pfizer for the treatment of primary immune thrombocytopenia (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP).

3. POSSIBLE ADVERSE EVENTS

This is the first study of PF-06755347 in people. Therefore, the full safety profile of PF-06755347 in humans is not known.

The study drug has been tested in animals. The following side effects were seen in some animals given PF-06755347 by intravenous (IV) administration:

- Increased heart rate
- Decreased blood pressure
- Increased blood pressure
- Bleeding
- Vomiting
- Lack of muscle coordination
- Elevations of cytokines and complement in blood test (proteins that regulate the immune system and control inflammation)
- Development of antibodies to PF-06755347

These animals had study drug levels in their blood that were at least 15 times ($\geq 15x$) higher than have been seen in people.

Animal deaths occurred only after more than 7 weekly IV doses of PF-06755347. The animal deaths were due to uncontrolled bleeding and/or clotting within the body and were observed only with high

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



doses of PF-06755347. No animal deaths or bleeding occurred in a 6-month study of weekly IV or subcutaneous (SC) administration where blood levels of PF-06755347 were four times (4x) higher than would be expected in people who receive the highest planned dose.

Animal studies do not always predict the side effects people may experience. If you do not understand any of the animal findings described above, please ask the study doctor to explain them to you.

Potential Drug Class Effects of PF-06755347

PF-06755347 is designed to act in a manner like another class of drugs called Immune Globulins (IG). IGs may be given intravenously (IVIG) or subcutaneously (SCIG). There are differences between PF-06755347 and IG, including a much lower amount of protein. However, some risks of IGs may also occur with PF-06755347 since they may act in a similar manner.

Some side effects of IG were also observed in this study and include headache, fever, chills, nausea, vomiting, back pain, joint pain and common cold.

Rare side effects of IGs (that have not been observed in this study) include thrombosis (blood clots), impaired kidney function or kidney failure, allergic/anaphylactic reaction, aseptic (sterile) meningitis (inflammation of the barrier that surrounds the brain), and abnormal breakdown of red blood cells, leading to anaemia and poor ability of blood to carry oxygen. PF-06755347 may or may not carry similar risks.

The most common side effects (observed in 10% or more participants) were:

1. Injection Site Reaction (only observed with SC administration)
2. Cytokine Release Syndrome
Fever or fever with very low blood pressure, (mostly observed with IV administration), see Serious Risks below
3. Headache (mostly observed with IV administration)
4. Back Pain (mostly observed with IV administration)
5. Reduced platelets in the blood
Platelets are small cells in the blood that are part of the clotting system. Platelet counts dropped 15 - 30% from baseline, between 3 and 12 hours after IV or SC dosing. Platelet counts below baseline lasted up to 6 days in the highest dose SC cohort. However, platelet count drop was greater in one participant at the highest IV dose given (see Serious Risks below). Platelet counts remained in the normal range in all but one participant (see Serious Risks below). No bleeding or bruising events have been reported in any healthy participant.
6. High D-dimer levels in blood tests
D-dimer is a protein in the blood that comes from breakdown of a blood clot. A small amount of D-dimer is normally present. High levels of this protein mean that the clotting system has been activated. No symptoms of blood clots were found in participants with high D-dimer levels. The clinical significance of high D-dimer levels after administration of study drug is not known.

Less commonly reported side effects in this study (observed in 5 – 9% of participants) were:

1. Nausea (only observed with IV administration)
2. Feeling cold (only observed with IV administration)
3. Dry mouth (only seen with IV administration)
4. Common Cold
5. Covid-19

Investigators reported that neither COVID-19 nor Common Cold were related to study drug.

B7801001-1002 **A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.**



Serious risks seen in the study with PF-06755347 include:

Cytokine Release Syndrome (fever with very low blood pressure)

One participant developed fever, headache, and low blood pressure in the first 4 hours after receiving an IV dose of study drug. Fever, low blood pressure and headache all resolved promptly after he received IV fluids and a single IV dose of hydrocortisone, with complete recovery to his previous state of health. He completed the study.

Another participant developed fever about 4 hours after receiving the highest IV dose of PF-06755347 used in the study. He had headache, nausea, vomiting, and a rapid heart rate. He became very lightheaded while walking to the bathroom and needed assistance returning to his bed. The lightheadedness resolved after he lay down. Fever, nausea, vomiting and rapid heart rate resolved within 12 hours. His platelet count dropped below the normal range to a low of 115,000/mcL, which was a drop of 30 - 40% from baseline. The low platelet count began about 3 hours after dosing and lasted 2 days. These platelet counts would not be expected to increase the risk of bleeding. D-dimer values were extremely elevated through the first 48 hours after dosing. D-dimer levels returned to normal by 72 hours. This participant experienced no bleeding events and had no clinical evidence of blood clots.

If you experience any of the above side effects, contact the study doctor and/or seek medical care. If you do not understand what all these side effects mean, please ask the study doctor or staff to explain them to you.

PF-06755347 is investigational and all its side effects are not known. There may be rare and unknown side effects. These could include reactions that may be life-threatening. It is important that you report all side effects as soon as they occur. You should report them whether you believe they are caused by the study drug.

If you experience any significant side effects, you should use caution by:

- Avoid using stairs
- Not driving a car
- Not swimming or bathing in a tub
- Not working with machinery or at heights

You may form antibodies to PF-06755347. An antibody is a type of protein. Antibodies help protect the body against attack by bacteria and viruses. There is also a chance that if you have these antibodies, this study drug or similar ones may not work for you in the future.

All drugs have a potential risk of an allergic reaction. If not treated promptly, it could become life-threatening.

You should get medical help and contact the study doctor right away if you think you have any of the following symptoms of a serious allergic reaction:

- Trouble breathing
- Wheezing
- Difficulty swallowing
- Swelling of the face, mouth, lips, gums, tongue, or neck

Other allergic reactions may include:

- Itchiness
- Rash
- Hives
- Blisters
- Palpitations (racing heart)
- Chest discomfort/tightness
- Muscle pains/stiffness

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



At times, the following may also be symptoms of an allergic reaction:

- Diarrhoea
- Nausea
- Vomiting
- Abdominal pain

Participants will have the following procedures done:

- Catheters will be inserted into a vein of your arm for safety and blood sampling.
- A heart monitor attached to the chest for a continuous reading of heart rhythm and rate
- Blood pressure, temperature and heart rate will be measured.
- A monitor will be placed on a finger to sense the amount of oxygen in your blood.

Participants who experience a significant side effect during the study may have the following additional procedures done:

- A catheter may be inserted into a vein in your arm so that you may be given IV fluids and/or medications
- Other tests or treatment may be administered as necessary for your safety including, but not limited to, additional blood draws, and collection of urine, stool, or other bodily fluids. Depending on the severity of your symptoms, you may be referred to outside medical providers or a hospital for additional evaluation and/or treatment

If you are not honest about any side effects, you have during the study, you may be harmed by staying in the study.

The effects of the study drug on the following are not known:

- Sperm
- Pregnancy
- Unborn child

Definitive studies of PF-06755347 on reproduction in animals have not been completed. The effects of the study drug on male or female fertility are not known at this time.

As a man, you should not donate sperm through the end of the study. You should use a male condom during sexual relations. If your sexual partner is a woman who is or could become pregnant, she should use highly effective contraception.

Other currently unknown risks and discomforts could appear. It is therefore very important that any new health problem is quickly reported to the doctor, regardless of whether you think it has to do with the study or not.

As with any study medicines research, unexpected side effects may occur. If any significant findings or side effects were to come to light during this study, you would be notified.

In this case, you will be asked to sign either an addendum to the consent form or a new informed consent form.

The study medicines will not be available after the study has ended.

Course of the study

1. COHORTS 1 TO 6 (ALREADY COMPLETED)

For participants in Cohorts 1 to 6 the study was planned to last for approximately 13 weeks and included:

- A selection examination;
- 1 treatment period of 10 days and 9 nights in the PCRU (from Day -2 to Day 8);
- 5 outpatient visits, occurring approximately 11, 15, 22, 29 and 36 days after the administration of the drug.

We could have asked to return to the PCRU for one additional outpatient visit after the last visit on Day 36 to collect blood samples for immunogenicity and safety assessments.

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



2. COHORTS 7 TO 12

For participants in Cohorts 7 to 12 the study is planned to last for approximately 19 weeks and includes:

- A selection examination;
- 1 treatment period of 10 days and 9 nights in the PCRU (from **Day -2*** to Day 8);
(*Admission may be on Day -2 or Day -1 depending on the events.)
- 7 outpatient visits, occurring approximately 11, 15, 22, 29, 36, 50 and 71 days after the administration of the drug.

We may ask you to return to the PCRU for one additional outpatient visit after your last visit on Day 71 to collect blood samples for immunogenicity and safety assessments.

3. SCREENING EXAMINATION

Before being allowed to take part in the study, you will undergo a complete medical examination, specifically an ECG as well as a blood pressure and heart rate measurements. Blood and urine samples (**for which you must have been fasting for at least 12 hours**) will be taken for laboratory tests and to screen for drugs. You will nevertheless be allowed to drink water.

A blood sample test will be also carried out for tuberculosis detection and a chest x-ray will be required as well.

You will also complete a questionnaire about your participation in clinical studies in the 365 days preceding this screening examination.

For hygiene reasons, you are requested to take a shower before this visit.

To make it easier for the ECG electrodes to adhere to the skin, we ask you not to apply a moisturizing cream on your body.

4. STUDY PERIOD

If you agree to take part in the study and meet all the conditions required to be enrolled in the study, you will undergo the tests and examinations described below (in sections 4.1-4.2).

For safety reason, procedures may be added at any time during the study to check on your health status.

When participating to the study, you must be able to come to the PCRU within 24 hours if we need to call you in for a check-up. We therefore ask you not to make any travel plans that will prevent you from respecting this condition.

The remainder of your laboratory test samples and of the samples used to determine the study medicine and biomarkers levels may be retained for storage up to 1 year following completion of the study (destroyed after this timeframe or earlier if not used). The samples may be used for evaluation of exploratory safety biomarkers, bioanalytical method, as well as for other internal exploratory purposes related to this study medicine.

4.1. Cohorts 1 to 6

- Physical examination at admission
- Blood and urine samples for laboratory tests (**for which you must have been fasting for at least 4 hours**): at admission on Day -2
- Detection of drugs in urine: at admission on Day -2
- Continuous cardiac monitoring on Day -2 during at least 2 hours and on Day 1 during at least 8 hours.
- Triplicate Electrocardiogram: 10 measurements
- Single Electrocardiogram: 3 measurements

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



- Monitoring of the level of oxygen in the blood: 21 measurements (see Oximetry in the section "Specific features of the study" page 12)
- Blood pressure, pulse rate, temperature: 20 measurements
- Triplicate blood pressure, pulse rate, temperature: 1 measurement
- Blood and Urine for laboratory tests: up to 16 samples
- Blood samples to determine the concentrations of the drug, biomarkers, and the immunogenicity: up to 18 occurrences
- Banked Biospecimen blood sample: 1 sample on Day 1
- Intravenous administration of the drug on Day 1
- Observation of the site where the drug is administered: 14 times

4.2. Cohorts 7, 8, 9, 10 (optional), 11 (optional) and 12 (optional, Japanese)

- Physical examination at admission
- Blood and urine samples for laboratory tests (**for which you must have been fasting for at least 4 hours**): at admission
- Detection of drugs in urine: at admission
- Triplicate Electrocardiogram: 8 measurements
- Single Electrocardiogram: 5 measurements
- Monitoring of the level of oxygen in the blood: 23 measurements (see Oximetry in the section "Specific features of the study" page 13)
- Blood pressure, pulse rate, temperature: 16 measurements
- Triplicate blood pressure, pulse rate, temperature: 1 measurement
- Blood and Urine for laboratory tests: up to 14 samples
- Blood samples to determine the concentrations of the drug, biomarkers, and the immunogenicity: up to 18 occurrences
- Banked Biospecimen blood sample: 1 sample on Day 1
- **Subcutaneous** administration of the drug on Day 1
- Observation of the site where the drug is administered: 15 times

5. TREATMENTS ADMINISTERED DURING THE STUDY

The planned treatments are:

5.1 Cohort 1 to Cohort 6

Single dose of PF-06755347 and placebo administered by intravenous infusion:

- **Cohort 1** – 0.01 mg/kg of PF-06755347 or placebo;
- **Cohort 2** – 0.03 mg/kg of PF-06755347 or placebo;
- **Cohort 3** – 0.1 mg/kg of PF-06755347 or placebo;
- **Cohort 4** – 0.3 mg/kg of PF-06755347 or placebo;
- **Cohort 5** – 1 mg/kg of PF-06755347 or placebo;
- **Cohort 6** – 0.7 mg/kg of PF-06755347 or placebo.

5.2. Cohorts 7, 8, 9, 10 (optional), 11 (optional) 12 (optional, Japanese)

The planned treatments are a single dose of PF-06755347 or placebo administered by subcutaneous injection.

- **Cohort 7** – 25 mg of PF-06755347 or placebo;
- **Cohort 8** – 50 mg of PF-06755347 or placebo;
- **Cohort 9** – 100 mg of PF-06755347 or placebo;
- **Cohort 10** – 200 mg of PF-06755347 or placebo;
- **Cohort 11** – 300 mg of PF-06755347 or placebo;

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



- **Cohort 12** – a dose less than or equivalent to a dose studied in previous cohorts and deemed safe and well tolerated of PF-06755347 or placebo.

5.3 For all cohorts:

Only one single participant will be dosed at a given time, the next dosing will only happen after a 96-hour safety monitoring period.

In total there will be a minimum of **120 hours** between each participant to allow for review of **96 hours** safety data.

All participants within each cohort will be dosed using a sequential dosing scheme.

The highest dose during this study will not exceed 1 mg/kg of PF-06755347 (for IV) and 300 mg (for SC).

Neither you nor the PCRU personnel will know whether you are receiving PF-06755347 or Placebo during the period in progress, but the staff will be able to obtain the study medicine identity if necessary.

PF-06755347/placebo will be administered in a random distribution determined by computer, which is also called randomization.

Contraception and pregnancy

At each visit to the PCRU, we will check that you are using the appropriate contraception.

If you have a partner, you may take part in this study on condition that you use condoms during your participation in the study and for the duration of the study until last contact.

So, you will amongst others prevent the possible transfer of the drug through the semen during the study.

In addition to that, if your partner is a woman, she will have to use one of the following contraception methods:

- Intrauterine device (IUD) or Intrauterine hormone-releasing system (IUS)
- hormonal contraception

OR has had bilateral tubal ligation/bilateral salpingectomy or bilateral tubal occlusive procedure

If you have had a vasectomy more than six months ago, or if your partner is post-menopausal or surgically sterilised, she will not need to use the contraception methods set forth above.

Taking the study medicine could bring about an unknown risk for an embryo, foetus or could negatively affect the quality of the sperm. It is important that you tell us if your partner is pregnant or if you plan to conceive during the study and up to completion of the study. You commit to inform your partner about your taking part in this study and the potential risks for an embryo or foetus.

You cannot donate sperm up to completion of the study.

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



PREGNANCY FOLLOW UP

If your partner becomes pregnant during the study, please inform the study doctor immediately. The study doctor will ask if you/your partner or your pregnancy doctor is willing to provide updates on the progress of the pregnancy and its outcome. If you/your partner agree, this information will be provided to the study sponsor for safety monitoring follow-up.

Benefits

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of drugs and treatments which will benefit other people.

Withdrawal from the study

Your participation is voluntary, and you are entitled to withdraw from the study for any reason, without having to justify your decision. Nevertheless, it may be useful for the investigator and for the sponsor of the study to know if you are withdrawing from the study because the constraints or discomfort of the treatment are too great (too many uncomfortable side effects, for example).

You may be asked if this decision to withdraw is just to stop receiving the study medicine or also to stop taking part in study procedures and/or post treatment study follow-up. If you agree to continue with the follow up part of the study, information about your health will continue to be collected as described above in the procedures.

If you disagree to continue with the follow up part of the study, you must inform the study doctor in writing.

The sponsor will use information and samples already collected from you in the study before your withdrawal.

It is also possible that the investigator withdraws you from the study because he/she thinks it is better for your health or because he/she finds out that you are not following the instructions given to participants.

Finally, the competent national or international authorities, the Ethics Committee that initially approved the study or the sponsor may decide to interrupt or discontinue the study because the information gathered shows that the investigational treatment causes more side effects or more serious side effects than anticipated, or for any other reason, such as, for example, the decision to stop research and development of the study medicine.

Samples of biological material collected during the study

1. BANKED BIOSPECIMEN SAMPLE

A 4 mL blood sample will be collected at Day -2 to study your biology (such as DNA, RNA, proteins, and metabolites see glossary page 14) to understand subjects' responses to the study medicines (such as safety findings or drug level). This sample is called "Pharmacogenomic banked biospecimen".

In addition, a 2.5 mL blood sample will be collected 8 times for **Cohorts 1 to 6** and 9 times for **Cohorts 7 to 12**.

These samples are called "Banked Biospecimen(s)"

The samples will be held by Pfizer for up to 50 years. Research results will not be communicated to you or your doctor.

Specimens will be stored in a Pfizer-designated facility, which is currently located at 2910 Fortune Circle West, Suite E, Indianapolis, Indiana, 46241 in the United States

B7801001-1002 **A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.**



The samples taken of your biological material are considered to be a “donation” and you should know that, as a matter of principle, you will not receive any financial benefit (royalties) related to the development of new therapies derived from the use of your donation of biological material and that could have commercial value.

If you withdraw your consent for participation in the study, you may contact the investigating physician to have the unused portion of your sample destroyed. The results obtained based on your samples before the withdrawal of your consent will remain the property of the sponsor of the study.

2. OPTIONAL USE OF YOUR BANKED SAMPLE

See section “**ADDITIONAL CONSENT REQUEST USE OF BIOLOGICAL SAMPLES FOR ADDITIONAL RESEARCH**” page 23.

If you take part in this clinical study, we ask you:

- To cooperate fully in the smooth running of this study.
- Not to conceal any information relating to your state of health, the medication you are taking or the symptoms you are experiencing.
- Not to take part in other clinical study involving an investigational treatment, be it a medicinal product, a medical device, or a procedure, while taking part in this study.
- To carry the "emergency card" with you at all times. This is imperative for your safety in the event of emergency care in an institution that does not know you. This card states that you are taking part in a clinical study. It also mentions a telephone number that you may call in an emergency. You should return this card to us at the end of the study.

Contact

If you need further information, but also if you have problems or concerns, you can contact the Pfizer Clinical Research Unit on the following telephone number +32 (0)2/556 70 02.

B7801001-
1002

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



II. Supplementary information

Restrictions

You should avoid all medications including non-prescription medicines bought, including vitamins, extracts of plants, homeopathic medicines, and medicinal herbal teas, in the four weeks before the study, throughout the study and up to the day of final payment. If you fall ill and require treatment, please contact the Unit immediately. You will be told what treatment you may undergo or whether it is possibly preferable to discontinue the study.

You must also avoid consuming any alcoholic drinks, stimulants (such as coffee, tea, chocolate, or beverages containing caffeine or theine), bread or cakes containing poppy seeds:

- from 24 hours before the screening examination until the results of your tests are known, **then**
- from 24 hours before the start and throughout each study period, **and lastly**
- from 24 hours before the check-up visit and up to the day of final payment.

You must also avoid any strenuous physical exercise:

- from 48 hours before the screening examination until the results of your tests are known, **and**
- from 48 hours before the start and throughout each study period, **and lastly**
- from 48 hours before the check-up visit and up to the day of final payment.

Exclusions

1. SPECIFIC EXCLUSIONS FROM THIS STUDY

You may not take part in this study if:

- You are outside of the age limits (18-55 years) or weight limits (minimum of 50 kg), or you are outside of the limits of the Body Mass Index (17.5 - 30.5 kg/m²).
- You show signs of active, latent, or inadequately treated tuberculosis.
- You show signs of general infections, heart failure or cancer.
- You have recurrent infections, or you had an infection recently.
- You have a history of coagulation disorders (e.g., thrombosis, bleeding).
- You have a history of autoimmune disorders and other conditions that compromise or impair the immune system (including but not limited to Crohn's Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves' disease).
- You have a history of migraine.
- You have a history of dyslipidaemia.
- You have received live vaccines within the 28 days prior to the screening visit.

Additional criterion for participants in the Japanese cohort only: Japanese participants who do not have four Japanese biologic grandparents born in Japan.

2. COMMON EXCLUSIONS TO MOST OF THE STUDIES

You may not take part in this study if:

- You are regularly taking medications, or you are suffering from a chronic illness.
- You are suffering from asthma or from any allergy to a medicine.
- You are suffering from any treated or symptomatic, seasonal allergies (hay fever) during the study.
- You smoke more than 5 cigarettes a day, or an equivalent quantity of tobacco
- You have taken part in another clinical study involving investigational medicines within the last 30 days. An approved COVID-19 vaccine is considered as a concomitant medication. Due to the potential for interference with vaccine efficacy, the last dose of an approved COVID-19 vaccine must be completed 28 days prior to dosing with PF-06755347.
- You have given blood, plasma, or constituent elements of blood during the two months preceding the study or you intend to be a donor in the two months following the end of the study (Red Cross standard to guarantee blood cells regeneration).
- You have taken or you are taking drugs.
- You think you are at risk of being infected with the AIDS virus, hepatitis B or C.

Specific features of the study

1. BLOOD VOLUME

The total quantity of blood taken during the study will be approximately **445 mL** for Cohorts **1 to 6**, **490 mL** for Cohorts **7 to 12** and **482 mL** for the Cohorts **13-14**.

The times for taking blood may change. Additional blood samples may be added provided the total volume of 550 mL is not exceeded.

Your body will quickly build up again this quantity of blood during the study.

2. INJECTION SITE CHECK

To be able to evaluate the tolerability of the study medicine we will examine the site of injection using a specific non-invasive test using a scale (for example: pain, skin reaction, etc....). This test will be performed several times during the study.

3. PICTURES

Pictures of the injection site should be taken. You will not be identifiable.

4. INTRAVENOUS CATHETER

A catheter is a thin flexible tube that can be inserted into a blood vessel (artery or vein), enabling blood samples to be taken or liquid to be injected.

The catheter will be placed on Day 1 in a vein in your forearm. You could feel a little pain when the catheter is placed.

B7801001-1002 **A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.**



5. SUBCUTANEOUS ADMINISTRATION

PF-06755347 will also be administered subcutaneously (under the skin) in possibly several locations of your body, such as the arms, thigh, or abdomen. During a subcutaneous injection, a needle is inserted under the skin, rather than into a vein, which allows the fluid to slowly enter the injection site. The injection sites will be determined by the PCRU staff.

6. OXIMETRY

We will ask you to wear an electrode on your finger. This electrode will enable us to determine the percentage of oxygen circulating in your blood. This analysis is completely painless.

7. CHEST RADIOGRAPHY

We will ask you to go to a radiology centre. The aim of this radiography is to exclude signs of active, latent, or inadequately treated tuberculosis, general infections, heart failure or cancer. This analysis is completely painless.

B7801001-
1002

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



Glossary

Antibodies: Proteins able to recognize molecules or pathogens, such as bacteria and viruses, as a harmful agent in your body.

Bilateral salpingectomy: Surgical removal of the fallopian tubes.

Bioanalytical method: Techniques used to measure the quantity of study medicine, metabolite, biomarkers, or proteins.

Biobank: Reserve of biological samples

Biomarker: A biomarker is a characteristic objectively measured and evaluated as an indicator of a disease or of the action of a medicine. Thus, for example, glucose is a biomarker for diabetes, and blood pressure is a biomarker for arterial hypertension (high blood pressure).

Body Mass Index: The Body Mass Index is calculated by dividing your weight (in kg) by your height (in m) squared. In practice, you just need to divide your weight by your height and then once again divide the result by your height. For example, if you are 1.70 m tall and you weigh 70 kg, your BMI index will be 24. This is calculated as follows: $70 \text{ kg} / 1.70 \text{ m} = 41$ and $41 / 1.70 \text{ m} = 24$.

Chronic inflammatory demyelinating polyneuropathy (CIDP): rare and progressive autoimmune disease that affects the nerves in the arms and legs.

Complement factors: The complement system is a part of the immune system.

Cytokines: Small proteins involved in the immune response signalling.

DNA: A molecule that is present in all cells, and which comprises the entire set of information necessary to the development and working of an organism. It is also the support of the heredity because it is wholly or partly transmitted during reproduction. It therefore carries the genetic information (the genotype) and constitutes the genome of living beings.

Dyslipidaemia: abnormal amount of lipids (e.g., triglycerides, cholesterol and/or fat phospholipids) in the blood.

Genotyping: The proteins that make up the machinery of the human organism are produced from chromosomes. The place on a chromosome that identifies a protein is called a gene. The analysis of a gene is called «genotyping».

Immunogenicity: Ability of a substance to induce an immune response

Metabolite: Compound resulting from the transformation of a medicine in a cell, in a tissue or in blood.

Oximetry: monitor placed on a finger to sense the amount of oxygen in the blood.

Pharmacodynamics (PD): The study of what the drug does to the body (mechanism, action).

Pharmacogenomics: study of the role of the genome in drug response.

Pharmacokinetics (PK): Assessment of the evolution of study drug concentrations in the blood before and after administration.

Placebo: is a substance or treatment which is designed to have no therapeutic value and is used as a control in testing new drugs.

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



Plasma: The liquid portion of the blood that bathes the other blood components (red blood cells, white blood cells, platelets).

Primary immune thrombocytopenia (ITP): disorder that can lead to easy or excessive bruising and bleeding. The bleeding results from unusually low levels of platelets — the cells that help blood clot.

Protein: Biological molecule composed of amino acids brought to the body through food processing by digestion followed by assimilation by the intestines, among others.

RNA: A biological molecule that is present in practically all living organisms, including certain viruses. The RNA is a molecule that is chemically very similar to DNA, and it is also in general synthesised in the cells based on a DNA matrix of which it is a copy. Living cells use RNA as an intermediary support for the genes to generate the proteins they need. The RNA can fulfil numerous other functions and intervene in chemical reactions taking place in the cell.

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



Additional information on protecting participants and their rights in each clinical study

You must inform the study doctor of:

- Any medicine or substance that you have taken in the last 28 days, that you are currently taking or that you intend to take;
- Any change in treatment that has taken place during the study;
- Any study exclusion criteria that would apply to you according to the information given by the doctor in charge;
- Any significant illness, past or present, including any consultation you have had with any doctor during the last six months, whether it resulted in medication or a drug prescription;
- Your history of drug taking alcohol consumption or smoking tobacco;
- Your participation in other clinical studies during the last 12 months.

Assistance or advice

This study has been submitted to an independent Ethics Committee 'Comité d'Ethique Hospitalo-Facultaire Erasme-ULB', which has issued a favourable ethical opinion as regards to its implementation. The Ethics Committees are responsible for the protection of the subjects who take part in clinical research in accordance with the Law of 7 May 2004 concerning experiments on humans.

However, the decision as to whether to participate in this study must be your own personal decision. Under no circumstances should you take the Ethics Committee's favourable opinion as an incentive to take part in this study.

If you have any questions, concerns or complaints concerning the role of the Ethics Committee or your rights as a participant in a clinical study, you may contact the Ethics Committee 'Comité d'Ethique Hospitalo-Facultaire Erasme-ULB', on the following number during office hours: 02/555 37 07.

A description of this clinical study will be available on <http://www.ClinicalTrials.gov>, as required by legislation. This website will not contain information that can identify you. It will be no more than a summary of the results. You can check this website at any time. However, it may be several years before the research results are available online.

The ClinicalTrials.gov website is in English only. If you would like any help in understanding the contents of this website, please talk to your study doctor.

Participant rights

Before signing, do not hesitate to ask any questions that you consider useful. Take the time to discuss it with a person you trust if you so wish.

Your participation in this study is voluntary and you must remain free from any constraint. This means that you have the right not to take part or withdraw at any time without giving any justification, without losing your legal rights, even if you previously agreed to take part in it.

If you decide to withdraw from the study, we ask you to inform the study doctor and to undergo some follow-up examinations so that we can be sure that you are in good health. The doctor in charge of the study can decide to remove you from the study if she/he deems that it would be harmful for you to continue to continue to take part to it. The study may also be discontinued further to the discovery of new information concerning the product or if the Ethics Committee takes a new decision on the study.

You will be informed of any new data that may influence your wish to take part or not in the study.

If you agree to take part in the study, you must sign the informed consent form. The study doctor, or designee, will also sign this form and will thereby confirm that she/he has provided you with all the necessary information on the study. You shall receive a paper copy of that document.

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



Compensation and insurance

Your compensation for the inconveniences caused by your participation to the study will be available three weeks after the last contact (see point 12 of the “Participant Agreement and Consent Form”).

Any clinical study carries a risk, however small it is. If you suffer damage because of your participation in this study, you (or in the event of death, your dependants) will be compensated for this damage by the study sponsor in accordance with Article 29 of the Belgian Law related to experiments on humans (7 May 2004). You do not have to prove fault for this. In this regard, the sponsor has taken out an insurance policy.

You are therefore asked to report any new health problem to the investigator before consulting another doctor, taking any other medication, or receiving any other medical treatment. If, for any reason, you consult another doctor during this clinical study, you must inform him/her that you are taking part in a clinical study and present your clinical study participant card. This could be important in establishing a diagnosis and treating your complaints.

If the investigator believes that a link with the study is possible (the insurance does not cover the natural progression of your disease or the known side effects of your normal treatment), he/she will inform the study sponsor, which will initiate the declaration procedure to the insurance company. The latter will appoint an expert - if it considers it necessary - to assess whether there is a link between your new health problems and the study.

In the event of disagreement either with the investigator or with the expert appointed by the insurance company and whenever you feel it is appropriate, you or - in case of death - your dependents may bring proceedings against the insurer directly in Belgium (Insurer: Chubb European Group SE, policy number: BECANA07085, Tel: +32 (2) 516 97 11).

The law provides that the insurer may be summoned to appear either before the judge of the location where the event giving rise to the damage occurred, or before the judge of your domicile, or before the judge of the insurer's registered offices.

Provision has been made for insurance to cover research injury liability of the sponsor established in relation to the clinical trial.

Protection of your personal data

Your participation in the study means that you accept that the study doctor will collect data about you as specified in this document (the “Personal Data”) such as name, postal address, email address, phone number, date and place of birth, sex, age, your general practitioner’s name (with your consent), bank details, as well as ethnic origin and data relating to your health status, and that the study sponsor (Pfizer) will use this Personal Data for research purposes as specified in this document, and for scientific and medical publications on that research (fully anonymously).

Your Personal Data will be collected, stored, accessed and otherwise processed in compliance with the applicable EU and Belgian laws on clinical trial, and with the applicable EU and Belgian privacy legislations as they may be amended or repealed and replaced from time to time (collectively referred to as “Data Privacy Laws”) and as specified in the annex “Supplement related to personal data protection” (p. 26).

You have the right to consult, correct or request deletion of your Personal data by writing to the following address: Participants Recruitment Department, Pfizer Clinical Research Unit, route de Lennik 808, 1070 Brussels. Should communicating your Personal Data potentially jeopardise the results of the study, we may ask you to wait until the end of the study to access these Personal Data.

If you want to ask for removal of Your Personal Data, please send a signed and dated letter to Participants Recruitment Department, Pfizer Clinical Research Unit, route de Lennik 808, 1070 Brussels. Your data will be deleted by Pfizer and will no longer be stored or processed by us (except for your letter requesting the removal – see point G of the “Supplement related to personal data protection”). You will therefore not be able to participate in any of our future studies.

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



However, if you have taken part in a study or a screening, we will not be able to delete your data, but your file will be inactivated, and you will not be contacted again.

Monitoring of non-participation in other clinical studies

Our Pfizer Clinical Research Unit, located on route de Lennik 808, 1070 Anderlecht (Brussels) takes part in the « Verified Clinical Trials LLC (“VCT”)” programme.

The aim of this database is to enable us to ensure that participants are not taking part in several phase I clinical studies at the same time. In addition, this system will enable us to enhance your protection, as well as the quality of the data for the study that you will be taking part in.

For more information regarding VCT, please refer to the separate VCT consent form.

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



(page left blank intentionally)

PARTICIPANT AGREEMENT AND CONSENT FORM

Principal Investigator	Dr Isabelle Huyghe
-------------------------------	---------------------------

1. I freely agree to take part in this study.
2. I have received full explanations from the people in charge of the study about the nature, purpose, and likely duration of the study, and about what is expected of me. I have also been informed of all the possible side effects. The information document, which was sent to me, is attached hereto and is an integral part thereof. I have informed the study doctor of my medical history, of the medications I may have taken, and of any other studies I may have participated in. In this regard, I was given the Study Information Leaflet pertaining to the abovementioned study.
3. I have been given the opportunity to question the study doctor on all aspects of the study and have understood the advice and information given as a result.
4. I have been informed that a blood sample will be taken for HIV, Hepatitis B and C screening. I have also been informed that blood samples will be taken, to study biological substances including my genes, to help us learn more about the study drug. The sample will be held in a Pfizer designated facility for up to 50 years.
Research results will not be communicated to me or my doctor.
5. I agree to comply with any instruction given during the study and to co-operate faithfully with the study doctor and to tell him/her immediately if I suffer any change of any kind in my health or well-being or any symptoms of whatever kind.
6. I undertake to be present on the premises of the Pfizer Clinical Research Unit for the whole period spent in hospital, and for the outpatient visits scheduled within the context of this study. I know non-compliance with this obligation could be detrimental to my health if I experienced an undesirable effect and could not immediately gain access to the appropriate medical care.
7. I shall not donate blood during the study, nor for two months before or after the trial.
8. I undertake to comply with the study restrictions as they are mentioned under "II Supplementary information" (page 11). If a violation of these commitments were confirmed by laboratory tests, I could be excluded from the study.
9. I understand that data about me will be collected throughout my participation in this study and that the Investigator and the Sponsor of the study will guarantee the confidentiality of these data.
I agree to my personal data being processed as described under "Protection of your personal data" in the section "Additional information on protecting participants [...]" (page 16). I also consent to these data being transferred to and processed in countries other than Belgium.
10. Although my name must never appear in the report of the study disclosed to third parties, I expressly authorise the company Pfizer to pass on the results of this study to the competent medical or pharmaceutical authorities, both Belgian and foreign, to technical advisers, whether linked to the company, and to publish the results.
11. It is understood that I am free to leave the study at any time without having to justify my decision and without losing my legal rights. However, I shall, in that case, continue to benefit from all treatments and check-ups my condition may require.

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



12. The company sponsoring the study confirms that:

- i) I shall receive the sum of **€2,545.00** (two thousand five hundred forty-five euros) for a participation of 13 weeks duration in this study.

I shall receive the sum of **€3,315.00** (three thousand three hundred fifteen euros) for a participation of 19 weeks duration in this study.

I shall receive the same amount, in full, if I need to withdraw from the study for medical reasons related to my participation in the study. If I withdraw from the study for medical reasons or other reasons not associated with my participation in the study, I will receive a proportional payment.

Should I have to come back for additional visits after the end of the study I shall receive **€250.00** (two hundred and fifty euros) per month and **€55.00 (fifty-five euros) for each visit.**

In case of changes made to the calendar as provided at the time of first dosing, the compensation amount will be reviewed accordingly.

Should my participation need to be ended for not respecting the restrictions, my compensation might be adapted.

In addition, **I will be reimbursed for my travel expenses** based on the journey from the address where I officially reside and the number of journeys made, when residing in Europe. When residing outside of Europe, **I will be reimbursed for my travel expenses once**, based on the journey from the address where I officially reside.

- ii) The sponsor has subscribed a no-fault insurance to cover injuries or significant deterioration in health or well-being in connection to my participation in the study.

13. I have been made aware of the reasons for which personal data will be processed and/or transferred as part of the study and of my legal rights concerning these personal data as described in the Participant Information Sheet.

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



Signatures:

In agreement, the participant:

Printed name of participant

Signature of participant

Date of signature[§]

§Participant/impartial witness must personally date their signature.

Person Obtaining Consent:

I hereby confirm having provided the participant with all the necessary information about the study, without exercising any pressure to cause the subject to participate. I further confirm that I have handed over a copy of the Information and Consent Leaflet signed by the participant and by me, and that I am willing to answer any additional questions if necessary. I state that I work in compliance with the ethical principles set out in the "Helsinki Declaration" and the Belgian Law of 7 May 2004 concerning experiments on humans.

Printed Name of the Person Conducting the Consent Discussion

Signature of the Person Conducting the Consent Discussion †

Date of Signature

†The investigator, or an appropriately qualified and trained person designated by the investigator to conduct the informed consent process, must sign and date the consent document during the same discussion when the participant signs the consent document.

Consent for Participant Who Cannot Read:

The study participant has indicated that he/she is unable to read. One or more members of the study team read the consent document to the study participant, discussed it with the study participant, and gave the study participant an opportunity to ask questions.

Printed name of impartial witness ‡

Signature of impartial witness

Date of signature[§]

Not applicable (*Check this box if the Signature of an impartial witness is not required. Signature of an impartial witness is required if the participant cannot read.*)

§Participant/impartial witness must personally date their signature.

‡ Impartial Witness: A person, who is independent of the study, who cannot be unfairly influenced by people involved with the study, who attends the informed consent process if the participant cannot read, and who reads the informed consent and any other written information supplied to the participant. See Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance.

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



**ADDITIONAL CONSENT REQUEST
USE OF BIOLOGICAL SAMPLES FOR ADDITIONAL RESEARCH
(OPTIONAL FOR PARTICIPANTS)**

- The Sponsor would like your permission to use some or all the samples collected in this study for additional research that may or may not be related to the study. This additional use of your sample(s) is called "Additional Research".
- If you decide to participate in this Additional Research, you do not have to provide any new samples because the sample(s) that have already been collected in the study will be used for this Additional Research.
- The below request is optional, and you do not have to agree. You may take part in the study and contribute samples for use in the study even if you do not want your samples to be used for Additional Research.

PURPOSE OF THIS ADDITIONAL RESEARCH

The aim of this Additional Research is to use these biological samples and the data obtained from them to understand diseases and to advance science, including development of other medicines or treatments.

- This Additional Research involves studying your biology. It may involve studying biological substances in your sample(s), including your genes.
- The Additional Research might include exploratory research of any disease or condition and is not limited to the disease or condition that is the focus of the study. It may not be possible to link the results of the exploratory research to individuals, including you. The sponsor does not plan to return information from this Additional Research to you or to the study Principal Investigator.

The sponsor may share the samples and data from them with other researchers and collaborators. Further information about this is explained in the privacy section below.

Specimens will be stored in a Pfizer-designated facility, for as long as they are useful for scientific research, which may be for up to 50 years.

POSSIBLE BENEFITS OF PARTICIPATING IN THIS ADDITIONAL RESEARCH

This Additional Research is for research purposes only. There is no direct benefit to you from taking part. Information learned from the Additional Research may help other people in the future and help in the development of new medicines or treatments.

WITHDRAWAL OF CONSENT

You can change your mind at any time about allowing your biological samples to be used for this Additional Research. Inform the study doctor that you would like to end your participation in the Additional Research.

COMPENSATION

You will not be compensated for taking part in this Additional Research.

The sponsor may use information from this Additional Research to develop products or processes from which the Sponsor could make a profit. There are no plans to pay you or provide you with any products developed from this Additional Research. The sponsor will own or have rights to all products or processes that are developed using information from your samples.

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



PRIVACY PROTECTION

See section “Protection of your personal data” (page 17).

CONTACT INFORMATION

The medical team will answer your questions or concerns regarding the Additional Research before, during, and after the research study.

Please refer to the main consent for contact information if you need to reach the medical team or wish to speak with someone not involved with the research study.

PARTICIPANT AGREEMENT AND CONSENT FORM FOR THE ADDITIONAL RESEARCH

1. I have read and understood the information about this Additional Research.
2. I have been given enough time and opportunity to ask about the details of the Additional Research and to decide whether to participate.
3. I voluntarily agree to take part in this Additional Research. I do not give up any of my legal rights by signing this consent document.
4. I have been informed that I will receive a signed and dated copy of this document.

First Name _____ Name _____ <hr/> Signature <hr/> Signature date	<p>YES, I AGREE TO MY SAMPLE(S) BEING USED FOR ADDITIONAL RESEARCH</p>
First Name _____ Name _____ <hr/> Signature <hr/> Signature date	<p>NO, I DO NOT AGREE TO MY SAMPLE(S) BEING USED FOR ADDITIONAL RESEARCH</p>

B7801001-1002 A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



SUPPLEMENT RELATED TO PERSONAL DATA PROTECTION

Table of Contents

A. What personal data may we collect about you during this study?	26
B. Who will use my personal data, how will they use it, and where will it be stored?.....	26
C. What happens to my personal data that is sent outside the study site?	27
D. How are my biological samples and images handled?.....	28
E. Can my personal data be used for other research?	28
F. How will my personal data be protected when transferred from the study site to the Sponsor?	29
G. What are my data protection rights? Whom may I contact about these rights or any concerns or complaints?	30
H. What happens if I do not wish to continue with the study?	30

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



This **Supplement related to personal data protection** describes how we will collect, use, and share your personal data. It also describes your rights as data subject of whom personal data are being collected and processed. Your personal data shall be processed in compliance with the General Data Protection Regulation and the Belgian law of 30 July 2018 relating to the protection of natural persons with regards to the processing of their personal data.

A. What personal data may we collect about you during this study?

The study team and others assisting with your study-related care will collect information related to you (personal data), in the framework of the study. Amongst these personal data; some are sensitive data. These data may include:

- **Information that directly identifies you** such as your name, address, telephone number, e-mail address, date and place of birth, national ID number.
- **Your bank details.**
- **With your consent, the identification of your general practitioner.**
- **Sensitive personal data** such as your medical history, data from this study (including study results from tests and procedures), demographics (for example, age and gender) and other sensitive personal data that is needed for this study such as ethnic origin, genetic information, sexual orientations, HIV/AIDS, tuberculosis, dietary preferences.
- **Data from testing and analysis of biological samples** (such as blood or urine) **and images** (such as X-rays, CT-Scans, and medical photographs). This may also include genetic information.
- **Data captured from electronic devices** if you complete the consent process using the eConsent tablet or if you use a mobile application or other digital tool during the study. This information may include data about your use of the eConsent tablet, application, or tool, such as the length of time it takes you to complete the consent process, the number of times you scroll between pages or click on the hyperlinked items, your electronic signature. Mobile applications and other digital tools used in the study may have their own privacy policies. Those policies provide additional information about the data processing activities performed by the digital tools.

B. Who will use my personal data, how will they use it, and where will it be stored?

Any personal data collected about you during this study will be stored by the study team at your study site. The study team must keep your personal data private.

Your personal data shall be accessed by:

- The study doctor and other study team members;
- The Sponsor and its representatives (including its affiliated companies);
- People, or organizations providing services for, or collaborating with, the Sponsor;
- Any organization that obtains all or part of the Sponsor's business or rights to the product under study;
- Government or regulatory authorities (including those in other countries); and
- Institutional Review Board(s) (IRB) or Independent Ethics Committee(s) (IEC) overseeing this study.

**B7801001-
1002**

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



The individuals and groups listed above will use your personal data to conduct this study, and to comply with legal or regulatory requirements, including to:

- determine if you are eligible for this study;
- provide you with reimbursement for your time, effort and certain expenses related to your participation;
- verify that the study is conducted correctly, and that study data are accurate;
- answer questions from IRB(s), IEC(s), or government or regulatory agencies;
- assess your use of electronic devices in the study, for example, to determine how long it takes you to complete any e-consent module used for the study and your comprehension of the e-consent process;
- contact you during and after the study (if necessary);
- follow-up on your health status, including using publicly available sources should the study team be unable to contact you using information held on file;
- protect your vital interests or the interests of your pregnant partner (for example, a critical medical situation, such as providing information to an emergency department of a hospital where you are being treated); and
- answer your data protection requests (if any).

The study site will retain your personal data for the period necessary to fulfil the purposes outlined in the consent document(s). This period could be up to 25 years after the end of the study.

If you provide someone else's personal data (for example, an emergency contact or details of family medical history) you should make them aware that you have provided the information to us. We will only use such personal data in accordance with this informed consent and applicable law.

C. What happens to my personal data that is sent outside the study site?

Before the study team transfers your personal data outside the study site, the study site will replace your name with a unique code and remove information that directly identifies you. We call this "**Coded Information**." The study site will keep the link between the code and your personal data confidential, and the Sponsor will not have access to that link. The Sponsor's employees and representatives are required to protect your Coded Information and will not attempt to re-identify you.

Your Coded Information will be used by the following persons:

- The Sponsor and its representatives (including its affiliated companies);
- People and/or organizations providing services to or collaborating with the Sponsor;
- Any organization that obtains all or part of the Sponsor's business or the rights to the product under study;
- Other researchers;
- The IRB or IEC that approved this study;
- Government or regulatory authorities, if necessary;

B7801001-
1002

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



The above parties may use your personal data for the following purposes:

- **Conducting the study**, including:
 - Examining your response to PF-06755347;
 - Understanding the study and the study results; and
 - Assessing the safety and efficacy of PF-06755347.
- **Complying with legal and regulatory duties** such as:
 - Ensuring the study is conducted according to good clinical practice;
 - Making required disclosures to IRB(s), IEC(s), or government or regulatory authorities;
 - Seeking approval from government or regulatory authorities to market PF-06755347 (it is possible that these government or regulatory authorities may disclose your Coded Information to other researchers for the conduct of future scientific research); and
 - Sharing study data with other researchers not affiliated with the Sponsor or study team (including through publication on the internet or other media). However, information that could directly identify you will not be made available to other researchers.
- **Publishing summaries of the study results** in medical journals, on the internet or at educational meetings of other researchers. You will not be directly identified in any publication or report of the study. But some journal representatives may need access to your Coded Information to verify the study results and ensure the research meets the journal's quality standards. Also, journals may require that genetic and other information from the study that does not directly identify you be made available to other researchers for further research projects.
- **Improving the quality, design and safety** of this study and other research studies.

The Sponsor will retain your Coded Information for the period necessary to fulfil the purposes outlined in the consent document(s). This period could be up to 25 years after the end of the study.

D. How are my biological samples and images handled?

If biological samples or images of you are taken during the study, those samples and images will be handled in the same way as your Coded Data. All samples will be treated as required by law. Sometimes your study site may be unable to remove information that can identify you from your images before sending images to the Sponsor and its representatives.

E. Can my personal data be used for other research?

Your Coded Information may be used to advance scientific research and public health in other projects that will occur in the future. Currently, we do not know the specific details of these future research projects. However, if your biological samples are collected, those samples, with their related data, will only be used for other research if you agree and confirm by signing the Additional Consent Request.

B7801001-
1002

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



This other research may be conducted (1) in combination with data from **other sources**, (2) for **additional scientific research purposes** beyond objectives of this study, and (3) subject to **specific safeguards**.

- **Other sources:** Coded Information may be combined with data from other sources that are taken from outside typical research settings. These sources may include coded electronic health records, claims and health care cost and payment data or databases, product and disease registries, data gathered through your phone, tablet, or other devices and mobile applications, social media, pharmacy data, biobanks, or patient engagement programs.
- **Additional scientific research:** Coded Information may be used to understand how to make new medicines, devices, diagnostic products, tools and/or other therapies that treat diseases and to improve future research. It may also be used to inform value, cost-effectiveness, and pricing, and to optimize access to medicines.
- **Specific safeguards** will be used to protect your Coded Information, which may include:
 - Limited access to Coded Information to specific individuals who will be bound to keep this information confidential and will be prohibited from attempting to re-identify your Coded Information.
 - Use of security measures to avoid data alteration, loss, and unauthorized access.
 - Anonymisation of the data by removing and/or replacing information from the Coded Information and/or destroying the link to the Coded Information.
 - Assessing data protection systems to identify and mitigate privacy risks, if any, associated to each additional scientific research purpose.
 - When required by applicable law, verification that the scientific research has obtained the approval of IECs, IRBs, or other similar review groups.

F. How will my personal data be protected when transferred from the study site to the Sponsor?

Your personal data will be treated in compliance with applicable data protection laws. The Sponsor and Pfizer Clinical Research Unit (PCRU) are controllers of your personal data. The PCRU will be the data controller of your personal data and the Sponsor will be the data controller of your Coded Information.

Some of the people using your personal data, including your Coded Information, may be based in countries other than those of the European Union (EU) and of the European Economic Area (EEA), including the United States. Data protection laws may be different in these countries. The European Commission has decided that some of these countries provide a level of data protection equivalent to the one available in the EU (the full list of these countries is available at this website https://ec.europa.eu/info/law/law-topic/data-protection/international-dimension-data-protection/adequacy-decisions_en).

The Sponsor and people working with the Sponsor will take steps to maintain the confidentiality of your personal data. If your personal data is transferred by the Sponsor from the EU, EEA, and/or Switzerland to other countries that have not yet been found by European Commission to meet requirements for protection of personal data, the Sponsor has in place standard EU data transfer agreements to protect your personal data. Please contact your study team to obtain a copy of these standard data transfer agreements.

B7801001-
1002

A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.



G. What are my data protection rights? Whom may I contact about these rights or any concerns or complaints?

If you wish to exercise any of the rights described below or have concerns about how your personal data is being handled, it is best to contact the PCRU and not the Sponsor of the study. Generally, the Sponsor will not know who you are (by name) because the Sponsor only holds your Coded Information, which does not include your name or other information that can identify you. Please contact the PCRU, the study team representative or PCRU Data Privacy Steward at the following address: Participants Recruitment Department, Pfizer Clinical Research Unit, route de Lennik 808, 1070 Brussels, Phone: 0800/99.256 or +32 2/556.70.02; Email: verespectyourprivacy@pfizer.com.

- You have the right to access your personal data that is held about you by the study team. To ensure the integrity of the study, you will not be able to review some of the data until after the study has been completed.
- You have the right to correct or update your personal data.
- You have the right to limit the collection and use of your personal data under certain circumstances (for example, if the information is inaccurate).
- You have the right to receive your personal data in a structured, commonly used, and machine-readable format (for example, in a readable text electronic file or chart) for your own purposes or for giving it to others. *You may not have the right to receive your personal data that have been used for public interest purposes (for example, for reporting incidents of disease to public health officials) or in the exercise of official authority vested in the Sponsor or the PCRU (for example, responding to information requests from public agencies or monitoring drug safety).*
- You have the right to request the deletion of your personal data if you are no longer participating in the study and you have withdrawn your consent to the use of your personal data as described in this document. *However, there are limits on the ability to honour a request to delete your personal data. Some or all your personal data may be kept and used if deletion would seriously impair the study (for example, if deletion would affect the consistency of study results) or if your personal data is needed to comply with legal requirements.*
- You have the right to file a complaint with a data protection authority:

Data Protection Authority

Rue de la Presse 35, 1000 Brussels

Tel.: +32 (0)2 274 48 00

Fax: +32 (0)2 274 48 35

Email: contact@apd-gba.be

<https://www.dataprotectionauthority.be/contact-us>

H. What happens if I do not wish to continue with the study?

As noted in the main consent document, you are free to stop taking part in this study at any time by informing the study team of it.

If you stop taking part in the study and you do not inform the study team, your contact information may be used by the study team to contact you and check whether you wish to continue in the study. If the study team is unable to reach you, the Sponsor may use publicly available records about your health to monitor the long-term safety of the study medicine. This will only be done if allowed by the law.

If you stop taking part in the study but do not withdraw your consent for the processing of your personal data, your personal data will continue to be used in accordance with this document and applicable law.

B7801001-1002 **A Phase 1 randomized, placebo-controlled study to evaluate safety, tolerability, and PK of PF-06755347 after SAD IV or SC dosing in HPs and by SC dosing in participants with persistent or chronic primary ITP.**



If you decide to withdraw your consent:

- You will no longer be able to participate in the study;
- No new information or samples will be collected about you or from you by the study team;
- The study team may still need to report any safety event that you may have experienced due to your participation in the study;
- Your personal data, including Coded Information, that has already been collected up to the time of your withdrawal of consent, will be kept and used by the Sponsor to guarantee the integrity of the study, to determine the safety effects of PF-06755347, to satisfy legal or regulatory requirements, and/or for any other purposes permitted under applicable data protection laws;
- Your personal data, including your Coded Information, will not be used for further scientific research. However, if your personal data has been anonymized so that the information does not identify you personally, that information may continue to be used for further scientific research (as described in Section E of this document), as permitted by applicable law; and
- Biological samples that have been collected but not analysed will no longer be used, unless permitted or required by applicable law.

You have the additional right to request that any remaining samples that have been collected from you as part of the study be destroyed. You may exercise this right by communicating to the study team your wish to have the samples destroyed. The study team will then send your coded request to the Sponsor. In some countries, local laws or regulations may require that your samples be destroyed or de-identified if you withdraw from the study, regardless of whether you specifically make such a request.

However, we cannot guarantee the destruction of samples because the sample may no longer be traceable to you, they may have been used up, or they may have been released to a third party. In those cases, it would not be possible to remove and destroy your biological samples and any related data.